Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vital KSK Holdings, Inc. (3151.T)
Tokyo, JP
Vital KSK Holdings, Inc. is a Japanese entity primarily involved in the wholesale distribution of pharmaceutical products. Its diverse wholesale operations also cover veterinary medications, agricultural chemicals and supplies, and various types of medical and nursing care equipment. Beyond its core distribution activities, the company manages a range of services including operating pharmacies, providing nursing care, transportation, insurance agency services, real estate management, and parking facilities. It also runs a mail-order business focused on health-related products and offers pharmacy dispensing services. Furthermore, Vital KSK Holdings provides medical management consulting and manufactures over-the-counter (OTC) drugs. The company was established in 2009 and maintains its headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.15% | +5.67% | -2.13% | +6.74% | +15.63% | +4.32% | +18.33% | +50.67% | +109.99% | +50.05% | +73.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+1.7% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+2.2% Q1'26: +73.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-0.1% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+0.7% Q1'26: +0.6% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+2.6% Q1'26: +2.3% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-1.4% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.84× ★ Q1'26: 0.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2018 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
|---|---|---|---|---|---|
| Revenue |
565.59B
est: 570.00B (-0.8%)
|
562.53B
est: 557.20B (+1.0%)
|
537.06B
est: 566.20B (-5.1%)
|
577.25B
est: 542.20B (+6.5%)
|
579.77B
est: 563.30B (+2.9%)
|
| EBITDA |
9.77B
est: 10.76B (-9.1%)
|
10.97B
est: 10.52B (+4.3%)
|
5.72B
est: 10.69B (-46.5%)
|
10.87B
est: 10.23B (+6.2%)
|
11.56B
est: 10.63B (+8.7%)
|
| EBIT |
2.38B
est: 7.43B (-67.9%)
|
7.31B
est: 7.26B (+0.7%)
|
2.52B
est: 7.38B (-65.9%)
|
7.75B
est: 7.06B (+9.7%)
|
8.21B
est: 7.34B (+11.8%)
|
| Net Income |
4.47B
est: 3.54B (+26.2%)
|
4.64B
est: 4.47B (+3.8%)
|
1.17B
est: 4.46B (-73.8%)
|
4.77B
est: 3.61B (+32.1%)
|
4.83B
est: 4.14B (+16.6%)
|
| SGA |
41.39B
est: 41.63B (-0.6%)
|
41.69B
est: 40.69B (+2.5%)
|
40.48B
est: 41.35B (-2.1%)
|
41.03B
est: 39.60B (+3.6%)
|
42.49B
est: 41.14B (+3.3%)
|
| EPS |
68.23
est: 72.20 (-5.5%)
|
83.33
est: 91.20 (-8.6%)
|
21.25
est: 91.00 (-76.6%)
|
87.88
est: 73.60 (+19.4%)
|
92.69
est: 84.50 (+9.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akira Teramura | Executive Officer and GM of Sales & Purchase Division | — | — |
| Hideo Takeda | Executive Officer and GM of Legal & Compliance Department | — | — |
| Hiroshi Hiratani | Executive Officer & In Charge of SCM & GM of GDP Management Dept. | — | — |
| Hiroshi Yokoyama | Executive Officer, Head of Corporate Plannning Office & Corporate Planning Department | — | — |
| Isao Kita | Director of Accounting & Finance and Director | — | — |
| Junshi Iguchi | Executive Vice President & Director | — | male |
| Kenta Sato | Executive Officer, Manager of Corporation Planning Department & Head of Corporate Communications Office | — | — |
| Shigemi Naito | Executive Officer & GM of General Affairs & Human Resources Department | — | — |
| Taisuke Murai | Chief Executive Officer, President & Representative Director | — | male |
| Takeshi Ichijo | Executive Vice President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3151.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
